Corcept TherapeuticsCORT
About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Employees: 352
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
125% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 28
63% more call options, than puts
Call options by funds: $54.3M | Put options by funds: $33.3M
40% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]
37% more capital invested
Capital invested by funds: $2.95B [Q2] → $4.04B (+$1.1B) [Q3]
11% more funds holding
Funds holding: 284 [Q2] → 315 (+31) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 104
3.53% less ownership
Funds ownership: 87.17% [Q2] → 83.64% (-3.53%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth 37% 1-year accuracy 71 / 192 met price target | 18%upside $80 | Buy Reiterated | 7 Feb 2025 |
Canaccord Genuity Edward Nash 65% 1-year accuracy 13 / 20 met price target | 92%upside $130 | Buy Maintained | 30 Jan 2025 |
Financial journalist opinion
Based on 11 articles about CORT published over the past 30 days









